Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 142300.0
(1.14%)
KRW 142300.0
(1.14%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -463.03 KRW | -275.05% |
| 2022 | 264.52 KRW | 135.26% |
| 2021 | -750.19 KRW | -1583.17% |
| 2020 | -44.57 KRW | -109.13% |
| 2019 | 488.26 KRW | 19.38% |
| 2018 | 408.98 KRW | -30.1% |
| 2017 | 585.10 KRW | 38.52% |
| 2016 | 422.40 KRW | -25.9% |
| 2015 | 570.03 KRW | -0.34% |
| 2014 | 572.00 KRW | 27.39% |
| 2013 | 449.00 KRW | 550.72% |
| 2012 | 69.00 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 7.64 KRW | -84.74% |
| 2024 Q1 | 50.08 KRW | -76.78% |
| 2023 Q3 | -535.30 KRW | -208.14% |
| 2023 Q4 | 215.65 KRW | 140.29% |
| 2023 FY | - KRW | -275.05% |
| 2023 Q1 | 16.13 KRW | 41.0% |
| 2023 Q2 | -173.72 KRW | -1177.0% |
| 2022 FY | - KRW | 135.26% |
| 2022 Q1 | 83.31 KRW | 131.79% |
| 2022 Q2 | 50.21 KRW | -39.73% |
| 2022 Q3 | 120.15 KRW | 139.29% |
| 2022 Q4 | 11.44 KRW | -90.48% |
| 2021 Q3 | -184.46 KRW | -65.63% |
| 2021 Q1 | -192.29 KRW | -182.84% |
| 2021 Q2 | -111.37 KRW | 42.08% |
| 2021 Q4 | -262.07 KRW | -42.07% |
| 2021 FY | - KRW | -1583.17% |
| 2020 Q2 | 90.83 KRW | 57.39% |
| 2020 FY | - KRW | -109.13% |
| 2020 Q4 | 232.11 KRW | 155.0% |
| 2020 Q3 | -422.00 KRW | -564.6% |
| 2020 Q1 | 57.71 KRW | 147.13% |
| 2019 Q2 | 122.60 KRW | -15.35% |
| 2019 Q1 | 144.83 KRW | 297.5% |
| 2019 FY | - KRW | 19.38% |
| 2019 Q4 | -122.45 KRW | -135.91% |
| 2019 Q3 | 341.00 KRW | 178.14% |
| 2018 Q2 | 171.00 KRW | 47.41% |
| 2018 Q3 | 194.92 KRW | 13.99% |
| 2018 Q4 | -73.33 KRW | -137.62% |
| 2018 FY | - KRW | -30.1% |
| 2018 Q1 | 116.00 KRW | -9.42% |
| 2017 Q1 | 168.99 KRW | 301.37% |
| 2017 FY | - KRW | 38.52% |
| 2017 Q4 | 128.07 KRW | -32.95% |
| 2017 Q2 | 96.30 KRW | -43.01% |
| 2017 Q3 | 191.00 KRW | 98.34% |
| 2016 FY | - KRW | -25.9% |
| 2016 Q3 | 165.00 KRW | -7.35% |
| 2016 Q4 | -83.92 KRW | -150.86% |
| 2016 Q2 | 178.08 KRW | 15.62% |
| 2016 Q1 | 154.02 KRW | 11.61% |
| 2015 FY | - KRW | -0.34% |
| 2015 Q3 | 160.00 KRW | 25.93% |
| 2015 Q4 | 138.00 KRW | -13.75% |
| 2015 Q2 | 127.05 KRW | -0.74% |
| 2015 Q1 | 128.00 KRW | 22.66% |
| 2014 Q2 | 147.16 KRW | -22.8% |
| 2014 Q1 | 190.61 KRW | 1415.18% |
| 2014 FY | - KRW | 27.39% |
| 2014 Q4 | 104.35 KRW | -21.54% |
| 2014 Q3 | 133.00 KRW | -9.62% |
| 2013 Q2 | 150.00 KRW | 24.89% |
| 2013 Q3 | 166.00 KRW | 10.67% |
| 2013 Q1 | 120.11 KRW | 0.0% |
| 2013 Q4 | 12.58 KRW | -92.42% |
| 2013 FY | - KRW | 550.72% |
| 2012 FY | - KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | -365.00 KRW | -26.858% |
| ST Pharm Co.,Ltd. | 1041.07 KRW | 144.476% |
| ABL Bio Inc. | -55.32 KRW | -737.003% |
| Cellid, Co., Ltd. | -1078.05 KRW | 57.049% |